dromlakhani Evaluate AED levels and adjust doses in women on estrogen replacement
STEP 1 — Gather Information
Collect patient's current AED regimen (drug, dose, frequency), estrogen replacement details (type, dose, start date), baseline AED level if available, and assess for seizure control or adverse effects.
STEP 2 — Rule In / Rule Out
Determine whether the prescribed AED is highly protein bound (>80%) (e.g., phenytoin, valproic acid, carbamazepine). If yes, proceed to level measurement; if no, rely on clinical assessment and routine follow‑up.
STEP 3 — Classify or Stratify
Measure the AED total serum level and compare it to the laboratory‑specific therapeutic range; classify as subtherapeutic, therapeutic, or supratherapeutic.
STEP 4 — Decide
If subtherapeutic, increase dose; if supratherapeutic, decrease dose; if therapeutic, maintain current dose; in all cases, recheck level after 1‑2 weeks or sooner if symptoms change.
Clinical Guardrails / Mimics / Pitfalls
Do not adjust dose based solely on total level for highly protein bound AEDs without considering free fraction or clinical status; avoid dose changes in asymptomatic patients with stable seizure control; remember estrogen raises CBG, SHBG, and TBG, which can elevate total levels of highly bound drugs while free fraction remains unchanged; monitor for both seizure recurrence and signs of toxicity (e.g., nystagmus, ataxia, sedation).
Concrete Clinical Example
A 32‑year‑old woman on transdermal estradiol 50 µg/day for hypopituitarism‑related central hypogonadism starts phenytoin 100 mg nightly for new‑onset seizures. After 2 weeks, her total phenytoin level is 24 µg/mL (therapeutic 10‑20 µg/mL) but she is seizure‑free and has no toxicity. Because estrogen increases protein binding, the free fraction is likely unchanged; the dose is maintained and level is rechecked in 4 weeks.
Source: Hormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2016, DOI:10.1210/jc.2016-2118